Clasificación en acciones
#29656
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Precio por acción
$0.68377137
Última sincronización: 2023-05-23
Capitalización bursátil
$20.23M
Comercio Medivir AB (publ) (MVIR-B)
Precio MVIR-B con Capital del mercado a B
Capitalización de mercado de Medivir AB (publ)(MVIR-B)
Capitalización bursátil: $20.23M
A fecha de August 2026, Medivir AB (publ) tiene una capitalización de mercado de $20.23M. Esto convierte a Medivir AB (publ) en la 29656th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Medivir AB (publ) desde 2000 hasta 2026
MVIR-B en comparación con los más populares 5 títulos stocks
| Precio por MVIR-B |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.304T
|
+26,223,386.25%
|
|
|
|
|
$4.650T
|
+22,992,217.07%
|
|
|
|
|
$4.151T
|
+20,521,496.58%
|
|
|
|
|
$3.628T
|
+17,936,781.47%
|
|
|
|
|
$2.844T
|
+14,062,012.31%
|
